16 completed, 5 not yet recruiting, 5 recruiting, 4 terminated. 38 Phase 2, 5 Phase 3, 3 Phase 1.
Follow Polyradiculoneuropathy: new trials by email Literature Review of Polyradiculoneuropathy trials Research Report on Polyradiculoneuropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome Empasiprubart IV, Empasiprubart Placebo IV, Intravenous immunoglobulin (IVIg) - Guillain-Barré Syndrome (GBS) | Phase 2 | Not yet recruiting | argenx | 63 | 2026-12-01 | 2026-10-28 |
| A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Empasiprubart IV - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Phase 2 / Phase 3 | Not yet recruiting | argenx | 6 | 2026-09-01 | 2026-06-10 |
| Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barré Syndrome(GREAT) Intravenous immunoglobulin (IVIG), Efgartigimod Alfa-Fcab - Guillain-Barré Syndrome | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 110 | 2026-09-01 | 2026-09-18 |
| An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Obinutuzumab β - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Obinutuzumab β | Phase 1 / Phase 2 | Not yet recruiting | Zhongming Qiu | 24 | 2026-07-15 | 2026-07-10 |
| An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Batoclimab - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Immunovant Sciences GmbH | 26 | 2025-08-28 | 2026-08-11 |
| Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy Rituximab - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Withdrawn | University of Kansas Medical Center | 2025-07-01 | 2025-09-17 | |
| A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) TAK-411 - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Phase 2 | Recruiting | Takeda | 36 | 2025-05-14 | 2026-11-03 |
| Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP NVG-2089 - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Nuvig Therapeutics, Inc. | 14 | 2025-04-25 | 2026-10-06 |
| Efgartigimod for the Treatment of Guillain-Barré Syndrome efgartigimod - Guillain-Barre Syndrome (GBS) | Phase 2 / Phase 3 | Not yet recruiting | Zhongming Qiu | 20 | 2025-04-13 | 2025-03-20 |
| Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases BAFF-R CART - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University General Hospital | 27 | 2025-04-10 | 2026-10-16 |
| Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Imeroprubart, Placebo - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Recruiting | Immunovant Sciences GmbH | 162 | 2025-03-18 | 2026-09-30 |
| Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome Efgartigimod Alfa-Fcab, Intravenous Immunoglobulin (IVIg) - Guillain-Barre Syndrome | Phase 2 | Withdrawn | Chafic Karam | 2024-09-10 | 2026-03-12 | |
| Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immunoadsorption, Immunoglobulins - CIDP | Phase 2 | Recruiting | University of Ulm | 20 | 2023-05-01 | 2026-05-01 |
| To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Immunovant Sciences GmbH | 94 | 2022-12-15 | 2026-08-11 |
| Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Nipocalimab, Placebo - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Phase 2 / Phase 3 | Recruiting | Janssen Research & Development, LLC | 201 | 2022-09-23 | 2026-11-03 |
| IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients plasmapheresis device, Intravenous immunoglobulin - Guillain-Barre Syndrome | Phase 2 / Phase 3 | Completed | Assiut University | 81 | 2021-09-01 | 2023-04-06 |
| Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) SAR445088 (IV), SAR445088 (SC) - Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 2 | Completed | Bioverativ, a Sanofi company | 98 | 2021-04-28 | 2025-10-28 |
| Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 PurWet, FurFat, PurApo - Sequelae of; Infection, Post Infection Glomerulonephritis | Phase 1 / Phase 2 | Unknown | All Natural Medicine Clinic, LLC | 2000 | 2021-03-01 | 2021-05-26 |
| A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Efgartigimod PH20 SC - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 2 | Active not recruiting | argenx | 229 | 2020-09-18 | 2026-11-04 |
| A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) efgartigimod PH20 SC in stage B, placebo in stage B - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 2 | Completed | argenx | 322 | 2020-04-15 | 2024-08-20 |
Showing 20 of 38. Sign in to see all of them.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (28) · Guillain-Barre Syndrome (10) · Autoimmune Diseases (3) · Myasthenia Gravis (2) · Neuromyelitis Optica (2) · Ageusia (1) · Anosmia (1) · Anxiety Disorders (1) · Arthritis, Reactive (1) · Autoimmune Diseases of the Nervous System (1) · Bipolar Disorder (1) · COVID-19 stress syndrome (1) · Charcot-Marie-Tooth Disease (1) · Demyelinating Diseases (1) · Depression (1)
Chronic Disease (38) · Disease Attributes (38) · Immune System Diseases (38) · Nervous System Diseases (38) · Neuromuscular Diseases (38) · Pathologic Processes (38) · Pathological Conditions, Signs and Symptoms (38) · Polyneuropathies (38) · Autoimmune Diseases of the Nervous System (37) · Demyelinating Diseases (37) · Peripheral Nervous System Diseases (37) · Autoimmune Diseases (35) · Post-Infectious Disorders (9) · Neurodegenerative Diseases (3)
Immunoglobulins, Intravenous (5) · Rituximab (3) · efgartigimod alfa (3) · rozanolixizumab (2) · 4-Aminopyridine (1) · Antilymphocyte Serum (1) · Biotin (1) · Carmustine (1) · Cyclophosphamide (1) · Cytarabine (1) · Etoposide (1) · Hematopoietic Stem Cell Transplantation (1) · Immunoglobulins (1) · Injections, Subcutaneous (1) · Interferon beta-1a (1)
argenx (4) · Immunovant Sciences GmbH (3) · Zhongming Qiu (2) · All Natural Medicine Clinic, LLC (1) · Assiut University (1) · Beijing Tiantan Hospital (1) · Biogen (1) · Bioverativ, a Sanofi company (1) · Chafic Karam (1) · FDA Office of Orphan Products Development (1) · Fred Hutchinson Cancer Center (1) · Hansa Biopharma AB (1) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · Istituto Clinico Humanitas (1) · Janssen Research & Development, LLC (1)
United States (20) · Germany (10) · France (9) · United Kingdom (9) · Italy (8) · Spain (8) · Belgium (7) · Denmark (7) · Netherlands (7) · Poland (7) · Serbia (6) · Canada (5) · China (5) · Romania (5) · Argentina (4)
Allan Ropper, MD (1) · Chafic Karam, MD (1) · Colin Quinn, MD (1) · Frederic Sedel, MD (1) · Jau-Shin Lou, MD, PhD (1) · Johannes Dorst, Prof (1) · Johannes Jakobsen, Dr., MD (1) · Kate Dawson, MD (1) · Leona Holmberg (1)
PMID 38729747, PMID 12084892, PMID 15703014, PMID 28975040, PMID 30121613, PMID 32594300, PMID 32997260, PMID 37119056, PMID 37899433, PMID 38205888, PMID 38353301, PMID 38729746, PMID 39304241, PMID 42578463
2019 (2), 2016 (1), 2018 (1), 2023 (1), 2025 (1)